Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page.SummaryDifference0.0%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding and potential updates/response delays has been removed from the page. This change does not affect the trial details, eligibility criteria, or study results presented on the NCT03238027 page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check35 days agoChange DetectedThe changes are limited to layout/formatting with no new eligibility criteria, endpoints, locations, or study status updated. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check64 days agoChange DetectedVersion bumped to v3.2.0 with an added government-operating-status notice; the previous v3.1.0 deletion indicates the page now reflects the updated version.SummaryDifference1%

- Check71 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check85 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed. No substantive changes to core content, pricing, stock, or time-related information.SummaryDifference0.1%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.